Tags

Type your tag names separated by a space and hit enter

Hypercalcemia of malignancy--new insights into an old syndrome.
Clin Lab. 2001; 47(1-2):67-71.CL

Abstract

Hypercalcemia is a common paraneoplastic syndrome. Tumors induce hypercalcemia by a local mechanism associated with the tumor's production of various cytokines increasing bone osteolysis. In addition, many tumors release humoral factors, mainly parathyroid hormone (PTH)-related protein (PTHrP), which stimulates bone resorption and/or tubular calcium reabsorption leading to hypercalcemia. Interaction of PTHrP with other tumor-elaborated cytokines might explain some nonPTH-like features associated with the hypercalcemia of malignancy syndrome. Using assays recognizing various PTHrP epitopes, the majority of hypercalcemic cancer patients have higher immunoreactive PTHrP levels in either plasma or urine than normal subjects. Present data support the concept that PTHrP might also be a factor which promotes tumor growth and also the development of osteolytic metastasis. A variety of therapeutic approaches are available to lower serum calcium in hypercalcemic cancer patients. The pathophysiological mechanisms of hypercalcemia appear to be a determinant of the efficacy of different antihypercalcemic treatments.

Authors+Show Affiliations

Esbrit P
Bone and Mineral Metabolism Laboratory, Research Unit, Fundación Jiménez Díaz, Madrid, Spain. pesbrit@fjd.es

MeSH

CytokinesHumansHypercalcemiaHyperparathyroidismNeoplasmsOsteolysisParathyroid Hormone-Related ProteinProteins

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

11214225

Citation

Esbrit, P. "Hypercalcemia of Malignancy--new Insights Into an Old Syndrome." Clinical Laboratory, vol. 47, no. 1-2, 2001, pp. 67-71.
Esbrit P. Hypercalcemia of malignancy--new insights into an old syndrome. Clin Lab. 2001;47(1-2):67-71.
Esbrit, P. (2001). Hypercalcemia of malignancy--new insights into an old syndrome. Clinical Laboratory, 47(1-2), 67-71.
Esbrit P. Hypercalcemia of Malignancy--new Insights Into an Old Syndrome. Clin Lab. 2001;47(1-2):67-71. PubMed PMID: 11214225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypercalcemia of malignancy--new insights into an old syndrome. A1 - Esbrit,P, PY - 2001/2/24/pubmed PY - 2001/3/27/medline PY - 2001/2/24/entrez SP - 67 EP - 71 JF - Clinical laboratory JO - Clin Lab VL - 47 IS - 1-2 N2 - Hypercalcemia is a common paraneoplastic syndrome. Tumors induce hypercalcemia by a local mechanism associated with the tumor's production of various cytokines increasing bone osteolysis. In addition, many tumors release humoral factors, mainly parathyroid hormone (PTH)-related protein (PTHrP), which stimulates bone resorption and/or tubular calcium reabsorption leading to hypercalcemia. Interaction of PTHrP with other tumor-elaborated cytokines might explain some nonPTH-like features associated with the hypercalcemia of malignancy syndrome. Using assays recognizing various PTHrP epitopes, the majority of hypercalcemic cancer patients have higher immunoreactive PTHrP levels in either plasma or urine than normal subjects. Present data support the concept that PTHrP might also be a factor which promotes tumor growth and also the development of osteolytic metastasis. A variety of therapeutic approaches are available to lower serum calcium in hypercalcemic cancer patients. The pathophysiological mechanisms of hypercalcemia appear to be a determinant of the efficacy of different antihypercalcemic treatments. SN - 1433-6510 UR - https://www.unboundmedicine.com/medline/citation/11214225/Hypercalcemia_of_malignancy__new_insights_into_an_old_syndrome_ DB - PRIME DP - Unbound Medicine ER -